Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

References

• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia; 2019. Available from: https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841. Accessed December 17, 2020.
   Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. doi:10.1038/nrdp.2015.67
   PubMed Web of Science ®Google Scholar
• Desai PR, Lawson KA, Barner JC, Rascati KL. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Serv Res. 2013;4(4):187–194. doi:10.1111/jphs.12027
   Google Scholar
• Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–676. doi:10.1016/j.biopsych.2005.04.034
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–1540. doi:10.1017/S0033291706008191
   PubMed Web of Science ®Google Scholar
• Albert M, McCaig LF. Emergency department visits related to schizophrenia among adults aged 18–64: United States, 2009–2011. NCHS Data Brief. 2015;215:1–8.
   Google Scholar
• Schoenbaum M, Sutherland JM, Chappel A, et al. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull. 2017;43(6):1262–1272. doi:10.1093/schbul/sbx009
   PubMed Web of Science ®Google Scholar
• Zhang W, Amos TB, Gutkin SW, et al. A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. Clinicoecon Outcomes Res. 2018;10:309–320. doi:10.2147/CEOR.S156308
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. GBD 2016 disease injury incidence prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Olfson M, Stroup TS, Huang C, et al. Suicide risk in Medicare patients with schizophrenia across the life span. JAMA Psychiatry. 2021;78(8):876–885. doi:10.1001/jamapsychiatry.2021.0841
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–1181. doi:10.1001/jamapsychiatry.2015.1737
   PubMed Web of Science ®Google Scholar
• Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry. 2018;75(3):254–260. doi:10.1001/jamapsychiatry.2017.4437
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi:10.1002/wps.20994
   PubMed Web of Science ®Google Scholar
• Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301. doi:10.1016/S2215-0366(17)30078-0
   PubMed Web of Science ®Google Scholar
• Kokurcan A, Safak Y. Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia. Saudi Med J. 2020;41(3):275–282. doi:10.15537/smj.2020.3.24909
   Web of Science ®Google Scholar
• DeRosse P, Nitzburg GC, Blair M, Malhotra AK. Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res. 2018;195:385–390. doi:10.1016/j.schres.2017.10.018
   PubMed Web of Science ®Google Scholar
• Dong M, Lu L, Zhang L, et al. Quality of life in schizophrenia: a meta-analysis of comparative studies. Psychiatric Quarterly. 2019;90(3):519–532. doi:10.1007/s11126-019-09633-4
   PubMed Web of Science ®Google Scholar
• Public Health Emergency. Determination that a public health emergency exists; 2020. Available from: https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx. Accessed December 20, 2021.
   Google Scholar
• Gannon JM, Conlogue J, Sherwood R, et al. Long acting injectable antipsychotic medications: ensuring care continuity during the COVID-19 pandemic restrictions. Schizophr Res. 2020;222:532–533. doi:10.1016/j.schres.2020.05.001
   PubMed Web of Science ®Google Scholar
• Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46(4):752–757. doi:10.1093/schbul/sbaa051
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561. doi:10.4088/JCP.14m09584
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization, and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017;17(1):207. doi:10.1186/s12888-017-1358-3
   PubMed Web of Science ®Google Scholar
• Pilon D, Tandon N, Lafeuille MH, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985.e. doi:10.1016/j.clinthera.2017.08.008
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. doi:10.1001/jamapsychiatry.2020.2076
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13(1):50. doi:10.1186/1471-244X-13-50
   PubMed Web of Science ®Google Scholar
• Druss BG. Addressing the COVID-19 pandemic in populations with serious mental illness. JAMA Psychiatry. 2020;77(9):891–892. doi:10.1001/jamapsychiatry.2020.0894
   PubMed Web of Science ®Google Scholar
• Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. doi:10.1016/S2215-0366(20)30090-0
   PubMed Web of Science ®Google Scholar
• Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients With COVID-19. JAMA Psychiatry. 2021;78(4):380–386. doi:10.1001/jamapsychiatry.2020.4442
   PubMed Web of Science ®Google Scholar
• Mazereel V, Vanbrabant T, Desplenter F, De Hert M. COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital. Lancet Psychiatry. 2021;8(10):860–861. doi:10.1016/S2215-0366(21)00301-1
   Web of Science ®Google Scholar
• Freudenreich O, Van Alphen MU, Lim C. The ABCs of successful vaccinations: a role for psychiatry. Curr Psychiatry. 2021;20(3):48–50. doi:10.12788/cp.0108
   Google Scholar
• U.S. Department of Health and Human Services. 45 CFR 46: pre-2018 requirements. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.101. Accessed October 16, 2020.
   Google Scholar
• American Psychiatric Association. COVID-19 pandemic guidance document: use of long-acting injectables as a clinically necessary treatment. Available from: https://www.psychiatry.org/File%20Library/Psychiatrists/APA-Guidance-Long-Acting-Injectables-COVID-19.pdf. Accessed October 29, 2021.
   Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. doi:10.1177/2045125312474019
   PubMedGoogle Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–264. doi:10.1093/oxfordjournals.schbul.a007076
   PubMed Web of Science ®Google Scholar
• Kokurcan A, Karadag H, Ercan Doğu S, Erid F, Orsel S. Clinical correlates of treatment adherence and insight in patients with schizophrenia. Archiv Clin Exp Med. 2020;5:95–99. doi:10.25000/acem.717027
   Google Scholar
• Pietrini F, Albert U, Ballerini A, et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1045–1060. doi:10.2147/NDT.S199048
   PubMed Web of Science ®Google Scholar
• Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge. Schizophr Res. 2020;220:265–266. doi:10.1016/j.schres.2020.04.030
   PubMed Web of Science ®Google Scholar
• Basit SA, Mathews N, Kunik ME. Telemedicine interventions for medication adherence in mental illness: a systematic review. Gen Hosp Psychiatry. 2020;62:28–36. doi:10.1016/j.genhosppsych.2019.11.004
   PubMed Web of Science ®Google Scholar
• Lawes-Wickwar S, McBain H, Mulligan K. Application and effectiveness of telehealth to support severe mental illness management: systematic review. JMIR Ment Health. 2018;5(4):e62. doi:10.2196/mental.8816
   Web of Science ®Google Scholar
• Flaherty LR, Daniels K, Luther J, Haas GL, Kasckow J. Reduction of medical hospitalizations in veterans with schizophrenia using home telehealth. Psychiatry Res. 2017;255:153–155. doi:10.1016/j.psychres.2017.05.024
   Web of Science ®Google Scholar
• Liberati E, Richards N, Parker J, et al. Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic. BMJ Open. 2021;11(4):e049210. doi:10.1136/bmjopen-2021-049210
   PubMed Web of Science ®Google Scholar
• Cipriani A. COVID-19 vaccination programme: where do people with mental health difficulties lie within the order of priority? BMJ Opin; 2021. Available from: https://blogs.bmj.com/bmj/2021/02/16/covid-19-vaccination-programme-where-do-people-with-mental-health-difficulties-lie-within-The-order-of-priority/. Accessed, October 29, 2021.
   Google Scholar
• American Psychiatric Association. COVID-19 pandemic guidance document: the role of the psychiatrist in the equitable distribution of the COVID-19 vaccine. Available from: https://www.psychiatry.org/FileLibrary/Psychiatrists/APA-Guidance-Psychiatrists-Role-in-Equitable-Distribution-COVID-19-Vaccine.pdf. Accessed October 29, 2021.
   Google Scholar
• Moreno C, Wykes T, Galderisi S, et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020;7(9):813–824. doi:10.1016/S2215-0366(20)30307-2
   PubMed Web of Science ®Google Scholar
• Lorenz RA, Norris MM, Norton LC, Westrick SC. Factors associated with influenza vaccination decisions among patients with mental illness. Int J Psychiatry Med. 2013;46(1):1–13. doi:10.2190/PM.46.1.a
   PubMed Web of Science ®Google Scholar
• Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 vaccine hesitancy—a scoping review of literature in high-income countries. Vaccines. 2021;9(8):900. doi:10.3390/vaccines9080900
   PubMed Web of Science ®Google Scholar